^
Association details:
| Biomarker: | CDKN2B mutation |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Padcev (enfortumab vedotin-ejfv) (Microtubule inhibitor, Nectin-4-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Biomarkers predictive of response to enfortumab vedotin (EV) treatment in advanced urothelial cancer (aUC).
Published date:
02/14/2022
Excerpt:
Pts with TP53 alterations had longer OS (NR vs 17.0 months, p=0.06) and PFS (NR vs 6.6 months, p=0.04) relative to wild-type pts. Shorter PFS was seen in pts with CDKN2A (4.4 months vs NR, p=0.05) and CDKN2B (4.3 months vs NR, p=0.02) alterations, but no differences in OS were observed....In this retrospective cohort of aUC pts with available NGS data, presence of TP53 and absence of CDKN2A and CDKN2B alterations were associated with favorable responses and improved clinical outcomes with EV, suggesting they may be biomarkers of response to EV.
DOI:
10.1200/JCO.2022.40.6_suppl.531
